Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia

Lydia L. Benitez; Anthony J. Perissinotti; Caitlin R. Rausch; Jeff Klaus; Stephen Michael Clark; Michael Filtz; Kelley Ratermann; Carissa Treptow; Shawn Griffin; Marissa Olson; Mallory Crain; Tapan Kadia; Kristen Pettit; Patrick W. Burke; Dale L. Bixby; Bernard L. Marini

doi:10.1080/10428194.2021.1907378

Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia

Lydia L. Benitez, Anthony J. Perissinotti, Caitlin R. Rausch, Jeff Klaus, Stephen Michael Clark, Michael Filtz, Kelley Ratermann, Carissa Treptow, Shawn Griffin, Marissa Olson, Mallory Crain, Tapan Kadia, Kristen Pettit, Patrick W. Burke, Dale L. Bixby, Bernard L. Marini

Leukemia

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 against regimens containing a purine analogue and high-dose cytarabine (HIDAC). This retrospective study compared complete response rates with/without count recovery (CR/CRi) between HIDAC-based regimens and CPX-351 in 169 patients with newly diagnosed sAML. The CR/CRi rate was 62.7% in the HIDAC-based therapy arm vs. 47.9% in the CPX-351 arm (p = 0.002 [one-sided for non-inferiority]). Median time to absolute neutrophil and platelet count recovery was shorter after HIDAC-based therapy (18 and 23 days, respectively) compared to CPX-351 (36 and 38 days; p < 0.001). Median overall survival was 9.8 months in the HIDAC-based group and 9.14 months in the CPX-351 group. 30-day mortality was greater with CPX-351 (8.5%) compared to HIDAC-based (1.3%; p = 0.039). These results reveal comparable efficacy and favorable safety with HIDAC-based regimens.

Original language	English (US)
Pages (from-to)	2184-2192
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	62
Issue number	9
DOIs	https://doi.org/10.1080/10428194.2021.1907378
State	Published - 2021

Keywords

CPX-351
FLAG
Vyxeos
cytarabine
oncology stewardship
secondary AML

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2021.1907378

Cite this

Benitez, L. L., Perissinotti, A. J., Rausch, C. R., Klaus, J., Clark, S. M., Filtz, M., Ratermann, K., Treptow, C., Griffin, S., Olson, M., Crain, M., Kadia, T., Pettit, K., Burke, P. W., Bixby, D. L., & Marini, B. L. (2021). Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leukemia and Lymphoma, 62(9), 2184-2192. https://doi.org/10.1080/10428194.2021.1907378

Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. / Benitez, Lydia L.; Perissinotti, Anthony J.; Rausch, Caitlin R. et al.
In: Leukemia and Lymphoma, Vol. 62, No. 9, 2021, p. 2184-2192.

Research output: Contribution to journal › Article › peer-review

Benitez, LL, Perissinotti, AJ, Rausch, CR, Klaus, J, Clark, SM, Filtz, M, Ratermann, K, Treptow, C, Griffin, S, Olson, M, Crain, M, Kadia, T, Pettit, K, Burke, PW, Bixby, DL & Marini, BL 2021, 'Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia', Leukemia and Lymphoma, vol. 62, no. 9, pp. 2184-2192. https://doi.org/10.1080/10428194.2021.1907378

@article{3fc5c659005d477ba6b34c762802a5cb,

title = "Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia",

abstract = "Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 against regimens containing a purine analogue and high-dose cytarabine (HIDAC). This retrospective study compared complete response rates with/without count recovery (CR/CRi) between HIDAC-based regimens and CPX-351 in 169 patients with newly diagnosed sAML. The CR/CRi rate was 62.7% in the HIDAC-based therapy arm vs. 47.9% in the CPX-351 arm (p = 0.002 [one-sided for non-inferiority]). Median time to absolute neutrophil and platelet count recovery was shorter after HIDAC-based therapy (18 and 23 days, respectively) compared to CPX-351 (36 and 38 days; p < 0.001). Median overall survival was 9.8 months in the HIDAC-based group and 9.14 months in the CPX-351 group. 30-day mortality was greater with CPX-351 (8.5%) compared to HIDAC-based (1.3%; p = 0.039). These results reveal comparable efficacy and favorable safety with HIDAC-based regimens.",

keywords = "CPX-351, FLAG, Vyxeos, cytarabine, oncology stewardship, secondary AML",

author = "Benitez, {Lydia L.} and Perissinotti, {Anthony J.} and Rausch, {Caitlin R.} and Jeff Klaus and Clark, {Stephen Michael} and Michael Filtz and Kelley Ratermann and Carissa Treptow and Shawn Griffin and Marissa Olson and Mallory Crain and Tapan Kadia and Kristen Pettit and Burke, {Patrick W.} and Bixby, {Dale L.} and Marini, {Bernard L.}",

note = "Publisher Copyright: {\textcopyright} 2021 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2021",

doi = "10.1080/10428194.2021.1907378",

language = "English (US)",

volume = "62",

pages = "2184--2192",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia

AU - Benitez, Lydia L.

AU - Perissinotti, Anthony J.

AU - Rausch, Caitlin R.

AU - Klaus, Jeff

AU - Clark, Stephen Michael

AU - Filtz, Michael

AU - Ratermann, Kelley

AU - Treptow, Carissa

AU - Griffin, Shawn

AU - Olson, Marissa

AU - Crain, Mallory

AU - Kadia, Tapan

AU - Pettit, Kristen

AU - Burke, Patrick W.

AU - Bixby, Dale L.

AU - Marini, Bernard L.

PY - 2021

Y1 - 2021

N2 - Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 against regimens containing a purine analogue and high-dose cytarabine (HIDAC). This retrospective study compared complete response rates with/without count recovery (CR/CRi) between HIDAC-based regimens and CPX-351 in 169 patients with newly diagnosed sAML. The CR/CRi rate was 62.7% in the HIDAC-based therapy arm vs. 47.9% in the CPX-351 arm (p = 0.002 [one-sided for non-inferiority]). Median time to absolute neutrophil and platelet count recovery was shorter after HIDAC-based therapy (18 and 23 days, respectively) compared to CPX-351 (36 and 38 days; p < 0.001). Median overall survival was 9.8 months in the HIDAC-based group and 9.14 months in the CPX-351 group. 30-day mortality was greater with CPX-351 (8.5%) compared to HIDAC-based (1.3%; p = 0.039). These results reveal comparable efficacy and favorable safety with HIDAC-based regimens.

AB - Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 against regimens containing a purine analogue and high-dose cytarabine (HIDAC). This retrospective study compared complete response rates with/without count recovery (CR/CRi) between HIDAC-based regimens and CPX-351 in 169 patients with newly diagnosed sAML. The CR/CRi rate was 62.7% in the HIDAC-based therapy arm vs. 47.9% in the CPX-351 arm (p = 0.002 [one-sided for non-inferiority]). Median time to absolute neutrophil and platelet count recovery was shorter after HIDAC-based therapy (18 and 23 days, respectively) compared to CPX-351 (36 and 38 days; p < 0.001). Median overall survival was 9.8 months in the HIDAC-based group and 9.14 months in the CPX-351 group. 30-day mortality was greater with CPX-351 (8.5%) compared to HIDAC-based (1.3%; p = 0.039). These results reveal comparable efficacy and favorable safety with HIDAC-based regimens.

KW - CPX-351

KW - FLAG

KW - Vyxeos

KW - cytarabine

KW - oncology stewardship

KW - secondary AML

UR - http://www.scopus.com/inward/record.url?scp=85104091736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104091736&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1907378

DO - 10.1080/10428194.2021.1907378

M3 - Article

C2 - 33830856

AN - SCOPUS:85104091736

SN - 1042-8194

VL - 62

SP - 2184

EP - 2192

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this